• English

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.

    Maryland Maternal Opioid Misuse (MOM) Model Provider Incentive Program

    Funded by the Center for Medicare and Medicaid Innovation, an overarching goal of the MOM model is to improve provider comfort and competency in treating pregnant and postpartum participants with opioid use disorder (OUD), including medication for OUD (MOUD), and to increase provider capacity in the more rural reaches of the state. Through its MOM model Provider Incentive Program, the Department aims to not only provide an incentive to providers who obtain a DATA 2000 waiver, but also to encourage waivered prescribers to treat to capacity, with wraparound support from technical assistance opportunities with the Maryland Addiction Consultation Service and utilization of clinical tools developed by the state’s Prescription Drug Monitoring Program. Increasing office-based buprenorphine-dispensing locations offers an opportunity to destigmatize receiving treatment for OUD for those reluctant to seek MOUD in an opioid treatment program setting. Incorporating MOUD services into a primary care or OB/GYN setting removes stigma by normalizing MOUD treatment in a traditionally somatic health-focused setting. Pending the availability of MOM model funding, the MOM model Provider Incentive Program will incentivize 20 providers per year from 2021 through 2024.
    For eligible provider types and regions, please refer to the MOM model Provider Incentive Program Letter of Intent Instructions (below).
    The Department acknowledges the recent U.S. Department of Health and Human Services release of Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder that eliminates the requirement for physicians to complete DATA 2000 waiver training and allows physicians with this exemption to treat up to 30 patients. For the purposes of the MOM model Provider Incentive Program, eligible physician prescribers must complete 8 hours of training per current protocols and not seek an exemption. 

    General Notice – 2021 MOM Model Provider Incentive Program Open for Applications

    The Maryland Department of Health (the Department) is accepting submissions for non-binding Letters of Intent (LOI) for the Provider Incentive Program funding opportunity. The Department will monitor progress of submissions to ensure completion. As an initiative of Maryland’s Maternal Opioid Misuse (MOM) model, the Department is offering reimbursement for undergoing DATA 2000 waiver to select provider types practicing in targeted jurisdictions to increase access to office-based buprenorphine in rural reaches of the state. Eligible provider types may submit LOIs for the Provider Incentive Program funding opportunity beginning January 1, 2021 and will have 90 days from the date the LOI is received to submit all materials to be eligible for $1,000 reimbursement of their time for obtaining a DATA 2000 waiver. The Department will accept twenty LOIs. Interested providers should carefully review the attestation form and LOI instructions available on the MOM model website. Please submit the Letter of Intent via email to mdh.mommodel@maryland.gov. LOIs will be accepted on a rolling basis until September 30, 2021, or as long as funds are available. This site will be updated once the submission limit has been reached for 2021.
    Application Materials:


    This project is supported by the Centers for Medicare and Medicaid Services (CMS) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $3.6 million with 100 percent funded by CMS/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CMS/HHS, or the U.S. Government.